Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;1410(1):68-84.
doi: 10.1111/nyas.13551.

Inflammatory biomarkers of low back pain and disc degeneration: a review

Aysha N Khan  1 , Hayley E Jacobsen  2 , Jansher Khan  1 , Christopher G Filippi  3 , Mitchell Levine  3 , Ronald A Lehman Jr  2   4 , K Daniel Riew  2   4 , Lawrence G Lenke  2   4 , Nadeen O Chahine  2   5
Affiliations
Review

Inflammatory biomarkers of low back pain and disc degeneration: a review

Aysha N Khan et al. Ann N Y Acad Sci. 2017 Dec.

Abstract

Biomarkers are biological characteristics that can be used to indicate health or disease. This paper reviews studies on biomarkers of low back pain (LBP) in human subjects. LBP is the leading cause of disability, caused by various spine-related disorders, including intervertebral disc degeneration, disc herniation, spinal stenosis, and facet arthritis. The focus of these studies is inflammatory mediators, because inflammation contributes to the pathogenesis of disc degeneration and associated pain mechanisms. Increasingly, studies suggest that the presence of inflammatory mediators can be measured systemically in the blood. These biomarkers may serve as novel tools for directing patient care. Currently, patient response to treatment is unpredictable with a significant rate of recurrence, and, while surgical treatments may provide anatomical correction and pain relief, they are invasive and costly. The review covers studies performed on populations with specific diagnoses and undefined origins of LBP. Since the natural history of LBP is progressive, the temporal nature of studies is categorized by duration of symptomology/disease. Related studies on changes in biomarkers with treatment are also reviewed. Ultimately, diagnostic biomarkers of LBP and spinal degeneration have the potential to shepherd an era of individualized spine medicine for personalized therapeutics in the treatment of LBP.

Keywords: back pain; biomarkers; inflammation; intervertebral disc degeneration; spine.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Spine and intervertebral disc anatomy in sagittal and cross-sectional views of healthy, degenerate, and herniated discs. Other potential disc changes are also shown in the sagittal view.
Figure 2
Figure 2
Summary of potential triggers, mediators, and disc consequences of inflammation and degradation contributing to LBP.
See this image and copyright information in PMC

References

    1. Hoy D, et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(6):968–974. - PubMed
    1. Deyo RA, Mirza SK, Martin BI. Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002. Spine (Phila Pa 1976) 2006;31(23):2724–2727. - PubMed
    1. Walker BF. The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. J Spinal Disord. 2000;13(3):205–217. - PubMed
    1. Hoy D, Brooks P, Blyth F, Buchbinder R. The Epidemiology of low back pain. Best Pract Res Clin Rheumatol. 2010;24(6):769–781. - PubMed
    1. Deyo RA, Tsui-Wu YJ. Descriptive epidemiology of low-back pain and its related medical care in the United States. Spine (Phila Pa 1976) 1987;12(3):264–268. - PubMed

MeSH terms